fda warning letters compounded semaglutide tirzepatide september 2025 versions of (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said Congress Introduces SAFE Drugs Act

Safe travels

It starts pulling back receptors

Therefore, before considering this kind of practice, always consult with your healthcare professionals to ensure safety and reduce associated risks

The REDEFINE Phase 3 program directly addressed this, showing CagriSema achieved 20.4% weight loss versus lesser results with semaglutide alone, cagrilintide alone, and placebo

Lean tirzepatide when: Maximum weight loss is the goal (target greater than 20%) You have T2D with significant insulin resistance (SURPASS-2: 11.2 kg tirzepatide vs 5.7 kg semaglutide) You have moderate-to-severe obstructive sleep apnea with obesity (Zepbound is the only FDA-approved pharmacotherapy) You plateaued on semaglutide after 12+ months You have MASH and need the drug with the strongest resolution data (SYNERGY-NASH: 44 to 62% resolution) Your insurance covers Zepbound or Mounjaro You tolerated the 2.5 mg starting dose well during a prior trial Lean semaglutide when: You have established cardiovascular disease or high CV risk

PlexusDx Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and can be prescribed with appropriate medical team coordination and informed consent from all providers involved in your care